How addictive are gabapentin and pregabalin? A systematic review
- PMID: 28988943
- DOI: 10.1016/j.euroneuro.2017.08.430
How addictive are gabapentin and pregabalin? A systematic review
Abstract
In the last ten years, gabapentin and pregabalin have been becoming dispensed broadly and sold on black markets, thereby, exposing millions to potential side-effects. Meanwhile, several pharmacovigilance-databases have warned for potential abuse liabilities and overdose fatalities in association with both gabapentinoids. To evaluate their addiction risk in more detail, we conducted a systematic review on PubMed/Scopus and included 106 studies. We did not find convincing evidence of a vigorous addictive power of gabapentinoids which is primarily suggested from their limited rewarding properties, marginal notes on relapses, and the very few cases with gabapentinoid-related behavioral dependence symptoms (ICD-10) in patients without a prior abuse history (N=4). In support, there was no publication about people who sought treatment for the use of gabapentinoids. Pregabalin appeared to be somewhat more addictive than gabapentin regarding the magnitude of behavioral dependence symptoms, transitions from prescription to self-administration, and the durability of the self-administrations. The principal population at risk for addiction of gabapentinoids consists of patients with other current or past substance use disorders (SUD), mostly opioid and multi-drug users, who preferred pregabalin. Pure overdoses of gabapentinoids appeared to be relative safe but can become lethal (pregabalin > gabapentin) in mixture with other psychoactive drugs, especially opioids again and sedatives. Based upon these results, we compared the addiction risks of gabapentin and pregabalin with those of traditional psychoactive substances and recommend that in patients with a history of SUD, gabapentinoids should be avoided or if indispensable, administered with caution by using a strict therapeutic and prescription monitoring.
Keywords: Abuse potential; Gabapentin; Liking; Overdose fatalities; Pregabalin; Wanting.
Copyright © 2017 Elsevier B.V. and ECNP. All rights reserved.
Similar articles
-
[On the risk of dependence on gabapentinoids].Fortschr Neurol Psychiatr. 2018 Feb;86(2):82-105. doi: 10.1055/s-0043-122392. Epub 2017 Nov 27. Fortschr Neurol Psychiatr. 2018. PMID: 29179227 German.
-
On the addictive power of gabapentinoids: a mini-review.Psychiatr Danub. 2018 Jun;30(2):142-149. doi: 10.24869/psyd.2018.142. Psychiatr Danub. 2018. PMID: 29930223 Review.
-
A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database.CNS Drugs. 2016 Jul;30(7):647-54. doi: 10.1007/s40263-016-0359-y. CNS Drugs. 2016. PMID: 27312320
-
Misuse and abuse of pregabalin and gabapentin: cause for concern?CNS Drugs. 2014 Jun;28(6):491-6. doi: 10.1007/s40263-014-0164-4. CNS Drugs. 2014. PMID: 24760436 Review.
-
A meta-analysis of the preoperative use of gabapentinoids for the treatment of acute postoperative pain following spinal surgery.Medicine (Baltimore). 2017 Sep;96(37):e8031. doi: 10.1097/MD.0000000000008031. Medicine (Baltimore). 2017. PMID: 28906391 Free PMC article. Review.
Cited by
-
Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis.Front Pharmacol. 2024 Jul 10;15:1385651. doi: 10.3389/fphar.2024.1385651. eCollection 2024. Front Pharmacol. 2024. PMID: 39050751 Free PMC article.
-
Trends in Pregabalin Use and Prescribing Patterns in the Adult Population: A 10-Year Pharmacoepidemiologic Study.CNS Drugs. 2024 Feb;38(2):153-162. doi: 10.1007/s40263-024-01064-5. Epub 2024 Jan 25. CNS Drugs. 2024. PMID: 38273137 Free PMC article.
-
Gabapentinoids: a therapeutic review.Aust Prescr. 2023 Dec;46(4):80-85. doi: 10.18773/austprescr.2023.025. Aust Prescr. 2023. PMID: 38152314 Free PMC article. Review.
-
The impact of a restricted pregabalin prescription policy on drug utilization: An observational multicenter study.Saudi Pharm J. 2023 Dec;31(12):101851. doi: 10.1016/j.jsps.2023.101851. Epub 2023 Oct 31. Saudi Pharm J. 2023. PMID: 38028223 Free PMC article.
-
Delirium following pregabalin discontinuation in an individual with no psychiatric or substance use history.BMJ Case Rep. 2023 Nov 17;16(11):e258104. doi: 10.1136/bcr-2023-258104. BMJ Case Rep. 2023. PMID: 37977830 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous